國藥現代(600420.SH):國藥威奇達的頭孢噻肟鈉、頭孢呋辛鈉、頭孢唑肟鈉獲得印度進口許可
格隆匯2月24日丨國藥現代(600420.SH)公佈,近日,上海現代製藥股份有限公司全資子公司國藥集團威奇達藥業有限公司(簡稱“國藥威奇達”)收到印度中央藥品標準管理局(英文全名:Central Drugs Standard Control Organisation,英文簡稱CDSCO)衞生和家庭福利部有關原料藥產品的進口許可。
涉及品種名稱:頭孢噻肟鈉、頭孢呋辛鈉、頭孢唑肟鈉。
頭孢噻肟鈉、頭孢呋辛鈉、頭孢唑肟鈉均屬於β-內酰胺類抗生素,具有抗菌譜廣、抗菌作用強、耐青黴素酶、過敏反應較青黴素類少見等優點,是高效、低毒、臨牀應用廣泛的重要抗生素。
根據健康網數據庫顯示,頭孢噻肟鈉2021年出口額約2308萬美元,國內主要生產廠家還有珠海聯邦制藥股份有限公司、山東瑞陽製藥股份有限公司等;頭孢呋辛鈉2021年出口額約617.50萬美元,國內主要生產廠家還有山東齊魯製藥集團有限公司、華北製藥河北華民藥業有限責任公司等;頭孢唑肟鈉2021年出口額約198萬美元,國內主要生產廠家還有山東齊魯製藥集團有限公司、山東羅欣醫藥集團股份有限公司等。
截至目前,國藥威奇達用於上述原料藥的累計研發投入約人民幣150萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.